Table I –
Cohort demographics
| Subject ID#1 | Age | Sex | Infection status2 | Days after symptom onset for blood/BAL collection3 | VFD4 | Died?5 | CLD?6 | CHF?7 | IS?8 | DM?9 | ESRD?10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1819B001 | 28 | F | Control | N/A | 28 | N | N | N | N | N | N |
| 1920B002 | 29 | M | Control | N/A | 28 | N | N | N | N | N | N |
| 1819B004 | 40 | F | Moderate Flu - IAV | D18 | 28 | N | N | N | N | N | N |
| 1819B007 | 27 | M | Moderate Flu - IAV | D9 | 28 | N | N | N | N | N | N |
| 1920B004 | 29 | F | Moderate Flu - IBV | D13, D48 | 28 | N | N | N | N | N | N |
| 1920B005 | 23 | F | Moderate Flu - IBV | D14, D59 | 28 | N | N | N | N | N | N |
| 1920B007 | 28 | F | Moderate Flu - IBV | D20 | 28 | N | N | N | N | N | N |
| 1920B008 | 31 | M | Moderate Flu - IAV | D14 | 28 | N | N | N | N | N | N |
| 1920B013 | 41 | M | Moderate Flu - IBV | D14 | 28 | N | N | N | N | N | N |
| 1920B011 | 26 | F | Severe Flu - IBV | D7 | 18 | N | Y | N | N | Y | N |
| 1920B014 | 50 | M | Severe Flu - IAV | D8 | 0 | N | N | N | N | N | N |
| MC-68 | 46 | M | Severe Flu - IAV | D8 | 0 | Y | Y | N | N | Y | N |
| MC-77 | 43 | F | Severe Flu - IAV | D7 | 8 | N | N | N | N | N | N |
| 350–174 | 74 | M | Severe COVID-19 | D10 | 0 | N | N | N | Y11 | Y | N |
| 350–428 | 59 | F | Severe COVID-19 | D11, D25 | 0 | N | Y | N | N | Y | N |
| 350–441 | 79 | M | Severe COVID-19 | D11 | 0 | Y | N | N | N | Y | N |
| 350–472 | 67 | M | Severe COVID-19 | D10 | 0 | Y | N | N | N | Y | N |
| C2 | 78 | F | Severe COVID-19 | D9 | 0 | Y | N | N | Y12 | N | N |
| C3 | 62 | M | Severe COVID-19 | D14 | 0 | Y | N | N | N | Y | N |
| C7 | 61 | F | Severe COVID-19 | D17 | 0 | Y | Y | N | N | Y | Y |
| C9 | 72 | F | Severe COVID-19 | D32 | 14 | N | Y | N | Y13 | N | N |
| C11 | 60 | F | Severe COVID-19 | D14 | 0 | Y | N | N | Y14 | Y | N |
| C12 | 53 | M | Severe COVID-19 | D11 | 0 | N | N | N | N | N | N |
| C14 | 74 | F | Severe COVID-19 | D14 | 0 | Y | N | N | N | Y | N |
| C15 | 66 | F | Severe COVID-19 | D6 | 0 | N | Y | N | N | Y | N |
| C16 | 73 | F | Severe COVID-19 | D13 | 0 | Y | N | N | Y15 | Y | N |
Footnotes:
Assigned study subject identification number;
Subject severity classification grouping and infecting virus: Control – healthy individuals who did not exhibit an influenza-like illness for at least 60 days prior to outpatient bronchoscopy and bronchoalveolar lavage (BAL) procedure; Moderate Flu – IAV/IBV – healthy individuals with symptomatic influenza A (IAV) or influenza B (IBV) virus infection that did not require hospitalization prior to outpatient bronchoscopy and BAL procedure; Severe Flu – IAV/IBV – individuals with severe IAV or IBV virus infection who were intubated for acute respiratory failure and BAL sampling was performed as a part of standard clinical care; Severe COVID-19 – individuals with severe COVID-19 who were intubated for acute respiratory failure and BAL sampling was performed as part of standard clinical care;
The number of days following the onset of symptoms of viral respiratory illness before each BAL sample was collected;
Ventilator Free Days – 28 days minus the number of days the subject required mechanical ventilation in the intensive care unit; individuals who expired on mechanical ventilation are set at 0;
Yes (Y) or No (N) that patient died during the index hospitalization;
Subject had a history of CLD (Chronic Lung Disease) of any type including asthma or COPD prior to infection;
Subject had a history of CHF (Congestive Heart Failure) prior to infection;
Subject had a history of IS (Immunosuppression) prior to infection;
Subject had a history of DM (Diabetes Mellitus) prior to infection;
Subject had a history of ESRD (End Stage Renal Disease) requiring dialysis prior to infection;
Subject 350–174 had a history of autoimmune disease and was on prednisone;
Subject C2 had a history of solid organ transplantation and was on mycophenolate and sirolimus;
Subject C9 had a history of solid organ transplantation and was on tacrolimus, mycophenolate and prednisone;
Subject C11 had a history of solid organ transplantation and was on tacrolimus;
Subject C16 had a history of autoimmune disease and was on prednisone and azathioprine